Last reviewed · How we verify

escitalopram and tramadol — Competitive Intelligence Brief

escitalopram and tramadol (escitalopram and tramadol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SSRI + opioid analgesic combination. Area: Psychiatry / Pain Management.

marketed SSRI + opioid analgesic combination Serotonin transporter (SERT), norepinephrine transporter (NET), mu-opioid receptor Psychiatry / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

escitalopram and tramadol (escitalopram and tramadol) — University of Southern Denmark. This combination pairs a selective serotonin reuptake inhibitor (escitalopram) with an opioid analgesic and norepinephrine reuptake inhibitor (tramadol) to treat depression and pain conditions.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
escitalopram and tramadol TARGET escitalopram and tramadol University of Southern Denmark marketed SSRI + opioid analgesic combination Serotonin transporter (SERT), norepinephrine transporter (NET), mu-opioid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SSRI + opioid analgesic combination class)

  1. University of Southern Denmark · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). escitalopram and tramadol — Competitive Intelligence Brief. https://druglandscape.com/ci/escitalopram-and-tramadol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: